Search Clinical Trials in the European Union

>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1681-1700 of 1,743 trials

Chronic Heart Failure: Combined Diuretic Therapy Study

We are comparing a new combined diuretic treatment to standard therapies for people with chronic heart failure. The goal is to see if it improves exercise capacity and fluid management.

Congestive Heart Failure>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCardiologyInternal Medicine

Metastatic Colorectal Cancer: New Diagnostic Test for Treatment Guidance

We are studying a new test to help doctors determine the best third-line therapy for patients with metastatic colorectal cancer. The goal is to see if this test provides accurate and reliable information for treatment decisions.

Metastatic Colorectal Cancer>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesInternal MedicineOncology

Metastatic Melanoma: V940 and Pembrolizumab Study

We are studying a new treatment combining V940 with pembrolizumab for people with metastatic melanoma. The aim is to see if this combination helps improve survival compared to a placebo.

Melanoma>2 yearsEfficacy phase (II)Investigational MedicinesCost ReimbursementOncology

Oxytocin Infusion: Effects on Sensory Nerves

We are studying how intravenous oxytocin affects sensory nerve responses and cognitive performance in healthy volunteers. This research may help us understand its role in pain perception and inflammation.

Healthy Participants>2 yearsSafety phase (I)≤5 visitsStandard MedicinesNeurologyPsychiatry

WSD0922-FU for Advanced Non-Small Cell Lung Cancer

We are studying a new treatment for patients with advanced NSCLC who have a specific mutation and did not respond to prior therapy. The goal is to see if this treatment can help shrink tumors and improve survival.

Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncologyPulmonology

Rezafungin for Fungal Infections in Critically Ill Patients

We are studying how Rezafungin levels change in patients on ECMO, a life-support treatment. This research aims to understand its effectiveness and any potential side effects.

Invasive Candidiasis>2 yearsConfirmation phase (III)Monitoring phase (IV)16-20 visitsNo PlaceboStandard MedicinesInfectious DiseasesInternal MedicinePulmonology

Narcolepsy and Idiopathic Hypersomnia: ALKS 2680 Study

We are investigating the safety and tolerability of ALKS 2680 for people with narcolepsy and idiopathic hypersomnia. The study also looks at its effects on excessive daytime sleepiness and cataplexy.

Narcolepsy and Idiopathic Hypersomnia>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Nucresiran for Transthyretin Amyloidosis with Cardiomyopathy

We are studying whether Nucresiran can help reduce serious heart-related events in patients with transthyretin amyloidosis. The trial compares its effects to a placebo to assess overall health improvements.

Transthyretin Amyloidosis with Cardiomyopathy>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementCardiologyInternal Medicine

Cerebrospinal Fluid Disorders: MRI Contrast Agent Study

We are testing a new MRI contrast agent to assess cerebrospinal fluid flow in adults with CSF disorders. This may help improve diagnosis and treatment of central nervous system conditions.

Idiopathic Intracranial HypertensionIntracranial CystsPrimary or Secondary Brain Cancer>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesNeurologyOtolaryngology

High-Risk Essential Thrombocythaemia: STP938 Treatment Study

We are evaluating a new medication for adults with high-risk essential thrombocythaemia who have not tolerated or responded to standard treatment. The study aims to assess its safety and early effects.

Essential Thrombocythaemia>2 yearsSafety phase (I)Hematology

CART84 Treatment for Relapsed Acute Leukemias

We are studying a new infusion treatment called CART84 for patients with relapsed or refractory acute myeloid leukemia and acute lymphoblastic T leukemia. The goal is to evaluate its safety and effectiveness in helping patients achieve remission.

Relapsed/Refractory Acute Lymphoblastic T Leukemia (T-ALL)Relapsed/Refractory Acute Myeloid Leukemia>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Infective Endocarditis: Oral vs. Parenteral Antibiotics

We are comparing oral antibiotics to outpatient parenteral antibiotics for treating infective endocarditis. The goal is to see if oral treatment is as effective and to assess patient satisfaction and costs.

Infective Endocarditis>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyInfectious Diseases

Kidney Transplant: Autologous Tolerogenic Dendritic Cells

We are testing a new treatment using patients' own immune cells to help highly sensitized kidney transplant recipients accept their new organ. This study aims to improve transplant success rates for these individuals.

Kidney Transplant>2 yearsSafety phase (I)NephrologyUrology

Rheumatoid Arthritis: Lower Dose of Rituximab Study

We are evaluating whether a 200 mg dose of Rituximab every six months is as effective as the standard 1 g dose for managing rheumatoid arthritis. This study will help us understand its impact on disease activity and overall patient well-being.

Rheumatoid Arthritis>2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementRheumatology

Breast Cancer Prevention: Exemestane vs. Tamoxifen

We are comparing two low-dose medications for post-menopausal women at high risk for breast cancer to see which one may improve quality of life and hormonal balance. This study aims to understand their effects over 12 months.

Breast Cancer>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesGynecology and ObstetricsOncology

Bladder Cancer: EMDA-MMC Treatment Study

We are evaluating a new treatment using electric current to deliver mitomycin C for high-grade non-muscle invasive bladder cancer. This study compares its effectiveness and safety to the standard BCG therapy.

Non-Muscle Invasive Bladder Cancer>2 yearsMonitoring phase (IV)11-15 visitsNo PlaceboStandard MedicinesOncologyUrology

Hairy Cell Leukemia: Vemurafenib and Rituximab Study

We are exploring a new treatment combination for hairy cell leukemia that may be less toxic than standard chemotherapy. This study aims to see if it is just as effective while monitoring patient safety and quality of life.

Hairy Cell Leukaemia>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesHematologyOncology

Ovarian Cancer: Sentinel Lymph Node Technique Study

We are evaluating a new technique to detect lymph node spread in early-stage ovarian cancer patients. This study aims to see how well it works compared to traditional methods.

Ovarian Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesGynecology and ObstetricsOncology

Rheumatoid Arthritis: Study of PIT565

We are testing a new treatment called PIT565 for individuals with rheumatoid arthritis. The study aims to understand its safety and how the body processes it.

Rheumatoid Arthritis>2 yearsSafety phase (I)Rheumatology

Metastatic Esophagogastric Cancer: MT-302 with CapOx

We are investigating the safety and early effectiveness of a new treatment, MT-302, combined with CapOx chemotherapy for patients with metastatic esophagogastric cancer.

Metastatic Esophagogastric Cancer>2 yearsSafety phase (I)Efficacy phase (II)Oncology